UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000047383
Receipt number R000053999
Scientific Title Experiences and Perceptions of Living with Generalised Pustular Psoriasis in Japan - Difference in Perspective between Patients and Physician
Date of disclosure of the study information 2022/04/04
Last modified on 2022/12/15 19:11:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Experiences and Perceptions of Living with Generalised Pustular Psoriasis in Japan - Difference in Perspective between Patients and Physician

Acronym

Experiences and Perceptions of Living with Generalised Pustular Psoriasis in Japan - Difference in Perspective between Patients and Physician

Scientific Title

Experiences and Perceptions of Living with Generalised Pustular Psoriasis in Japan - Difference in Perspective between Patients and Physician

Scientific Title:Acronym

Experiences and Perceptions of Living with Generalised Pustular Psoriasis in Japan - Difference in Perspective between Patients and Physician

Region

Japan


Condition

Condition

Generalised Pustular Psoriasis

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate experiences and perceptions of patients of living with generalised pustular psoriasis and treatment they have received as well as of physicians who treat generalised pustular psoriasis, and to identify any difference in perspective between patients and physicians.

Basic objectives2

Others

Basic objectives -Others

Not applicable

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Patient demographics, pathway to diagnosis and treatment, symptoms and conditions associated with generalised pustular psoriasis, patient burden in daily life and its awareness by others, patient-physician communication

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Inclusion Criteria:
Patient
1) A patient with diagnosis of generalised pustular psoriasis
2) 18 years of age or older

Physician
1) A physician currently treating one or more patients with generalised pustular psoriasis
2) A physician working mainly in the dermatology department at a Japanese Dermatological Association approved site for biologic products

Key exclusion criteria

Exclusion Criteria:
Patient
1) Inability to provide informed consent or complete the survey at treating physician's discretion

Physician
None

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Nobutaka
Middle name
Last name Yagi

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Division name

Patient Engagement

Zip code

141-6017

Address

2-1-1 Osaki, Shinagawa-ku,Tokyo, JAPAN

TEL

0364172043

Email

nobutaka.yagi@boehringer-ingelheim.com


Public contact

Name of contact person

1st name Nobutaka
Middle name
Last name Yagi

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Division name

Patient Engagement

Zip code

141-6017

Address

2-1-1 Osaki, Shinagawa-ku,Tokyo, JAPAN

TEL

03-6417-2043

Homepage URL


Email

nobutaka.yagi@boehringer-ingelheim.com


Sponsor or person

Institute

Nippon Boehringer Ingelheim Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation Kyoso-kai AMC Nishi-Umeda Clinic Ethics Review Committee

Address

Maruit Nishi-Umeda Building 3F, 3-3-45 Umeda, Kita-ku, Osaka-shi, Osaka, Japan

Tel

0647975660

Email

morikawa@amc-clinic.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 04 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 03 Month 16 Day

Date of IRB

2022 Year 03 Month 25 Day

Anticipated trial start date

2022 Year 04 Month 01 Day

Last follow-up date

2022 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Non-interventional study


Management information

Registered date

2022 Year 04 Month 04 Day

Last modified on

2022 Year 12 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053999


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name